How Does Parkinson’s Prevalence Differ in Different Regions of Europe, What Percentage of Adults Are Affected, and How Do Healthcare Policies Compare?
By mr.hotsia
This article is written by mr.hotsia, a long term traveler and storyteller who has spent years exploring Thailand, Laos, Vietnam, Cambodia, Myanmar, India and many other Asian countries. Along the way, he has seen that geography does not only change language and food. It changes how illness is noticed, diagnosed, treated, and lived with. Parkinson’s disease in Europe is a good example. The biology may be the same, but the burden and the care pathway are not evenly spread across the map.
🌍 Why This Question Is Harder Than It Looks
At first glance, this sounds like a simple question: which part of Europe has more Parkinson’s disease, and by how much? But the evidence is not arranged in one neat table for Western, Northern, Southern, Central, and Eastern Europe using the same denominator and the same method. Many studies report age-standardized rates, others report crude prevalence, and many modern papers give country-level estimates rather than a clean regional percentage for adults. Older European reviews also showed that prevalence estimates across Europe varied widely depending on study design and case finding.
So the most honest way to answer is not to pretend there is one perfect Europe-wide grid. It is to combine large European and global burden reports with strong country examples from different parts of Europe. That gives a more grounded picture and avoids the classic trap of comparing numbers that were not measured the same way.
📊 How Common Is Parkinson’s Disease in Europe Overall?
A widely cited Parkinson’s Europe figure is that around 1.2 million people in Europe are living with Parkinson’s disease. That makes it a major continental health burden already, even before counting the future increase expected with population ageing.
If the question is asked as a percentage of adults, the cleanest answer is that Parkinson’s disease in Europe usually sits in the low tenths of a percent in the general adult population, not in whole percentages. In contemporary national datasets from different parts of Europe, general-population prevalence often lands around 0.2% to 0.35%. For example, a nationwide Norwegian study found average prevalence of 0.20% in women and 0.23% in men in the general population, Germany reported 0.35% of the population in 2022, Italy’s systematic review estimated 193.7 per 100,000 or about 0.19%, and Poland reported 269 per 100,000 or about 0.27% by 2019. Because Parkinson’s is rare in children and concentrated in later life, the percentage among adults is slightly higher than these whole-population figures, and the prevalence rises sharply in older age groups.
So if someone wants one plain-language number, a fair summary is this: in Europe, Parkinson’s usually affects around two to four adults per 1,000 in broad population terms, but the share becomes much higher in older adults. In Germany, for instance, prevalence was reported as 0.61% from age 40 and 1.42% from age 65.
🧭 Does Prevalence Differ by Region of Europe?
Yes, but the difference is not a simple north-versus-south cartoon. The stronger signal is that Western Europe carries a heavier overall burden and is expected to grow faster in case numbers than Central and Eastern Europe, largely because of older populations, longer life expectancy, and higher diagnostic capture. A major 2025 projection based on GBD 2021 data estimated that Parkinson’s cases in Western Europe will rise by about 50% by 2050, while Central and Eastern Europe are projected to rise by about 28%. A 2024 systematic review also found higher prevalence in populations with higher GDP per capita and higher life expectancy, which fits the Western European pattern.
That said, when you look at representative country studies, the regional differences are not wildly dramatic in the way some people expect. Italy’s pooled prevalence of about 0.19%, Norway’s 0.20% to 0.23%, Poland’s 0.27%, and Germany’s 0.35% suggest that much of Europe lives within the same broad low-single-per-thousand band, even if Western and Central countries often appear somewhat higher. In other words, the regional gap is real, but it is more of a gradient than a cliff.
This is why it is safer to say that Western Europe appears to have a heavier diagnosed burden, while Central and Eastern Europe often show lower projected growth or lower recorded rates, rather than claiming that one half of Europe is completely different from the other. Part of what looks like “prevalence difference” may also reflect diagnosis patterns, age structure, and survival, not only raw disease biology.
🏥 How Do Healthcare Policies and Care Models Compare Across Europe?
This is where the contrast becomes much sharper.
A 2024 Parkinson’s Europe roundtable report described vast variation in care pathways and available services across Europe, including differences both between and within countries. The report explicitly said this creates a “postcode lottery” for patients, affecting referral, support, and access to advanced treatments. It also highlighted shortages of healthcare staff, lack of consistently available multidisciplinary teams, uneven integration of specialist nurses, and the fact that telemedicine and data-sharing tools are still not systematically adopted into standard Parkinson’s care.
So while Europe is often discussed as one healthcare region, Parkinson’s care is still not one single European system. Some countries and regions have built structured, specialized networks. Others remain far more fragmented. Rural-urban gaps also remain important. The same patient with the same disease may move from one postcode to another and find a very different treatment journey.
🇳🇱 Western and Northwestern Europe: More Structured Network Models
The Netherlands is often treated as a model case because of ParkinsonNet, an integrated and person-centered network-care model built around Parkinson-specialized professionals. Current Dutch implementation material describes ParkinsonNet as an established model of care, and the ACTION-PD program is now trying to roll versions of that model into parts of Poland, Italy, and France. That alone tells you something important: not every European country already has this level of organized Parkinson-specific network care.
Germany also stands out with its reimbursed Parkinson’s Disease Multimodal Complex Therapy (PD-MCT). A 2025 expert review described PD-MCT as a specialized inpatient multidisciplinary concept that is now used in over 200 hospitals in Germany and embedded in the German reimbursement system. That is a much more formal policy structure than what exists in many other European systems.
These examples matter because they show what “policy difference” looks like in real life. It is not only about whether a neurologist exists. It is about whether the health system actually funds coordinated Parkinson-specific rehabilitation, nurse support, education, and follow-up.
🇫🇷 🇸🇪 🇪🇸 Other European Policy Signals
The same 2024 European roundtable report noted that in France, chronic diseases including Parkinson’s are fully covered by health insurance, but this broad coverage can sometimes hinder adoption of more integrated support models because the structure of reimbursement does not always reward coordinated care. That is a subtle but important policy point: generous coverage alone does not automatically create good integration.
The report also highlighted case studies involving telemedicine in Sweden, home-neurology support in Brittany, and accredited advanced-care models in Spain, suggesting that some countries are moving toward more modern and flexible care pathways. But the very need to showcase these as case studies also underlines that such approaches are still not uniformly embedded across Europe.
🇵🇱 🇱🇻 Central and Eastern Europe: Improvement, but More Fragmentation
Central and Eastern Europe are not policy deserts, but the pattern is generally more uneven. Parkinson’s Europe’s policy documents place heavy emphasis on underserved areas, workforce planning, and cross-national training precisely because access is not uniform across the continent. A recent Latvian pilot study also reported substantial regional and systemic disparities in Parkinson’s care, with unequal access to neurologist services. That fits the broader European concern that access in parts of Central and Eastern Europe can still depend too much on where the patient lives.
It is important, though, not to reduce this to an East-versus-West stereotype. Fragmentation also exists in Western Europe, and some Central European countries are now part of projects specifically designed to import and adapt stronger network-care models. The more accurate picture is that northwestern Europe currently has more mature Parkinson-specific care structures, while parts of Central and Eastern Europe are still catching up in integration, specialist access, and advanced-treatment pathways.
✅ The Bottom Line
Parkinson’s disease in Europe does differ by region, but not in a neat classroom-chart way. The clearest pattern is that Western Europe carries a heavier diagnosed burden and is projected to see faster growth in case numbers than Central and Eastern Europe, largely because of ageing and demographic structure. Across representative national studies, the proportion of the whole population living with Parkinson’s usually falls around 0.19% to 0.35%, which translates to roughly 0.2% to 0.4% of adults in broad terms, with much higher percentages in older age groups.
The policy differences are sharper than the prevalence differences. Europe still has a postcode lottery in Parkinson’s care. Countries such as the Netherlands and Germany have more formalized network or multidisciplinary models, while many other parts of Europe still struggle with patchy nurse integration, slower referrals, rural access gaps, and inconsistent use of telemedicine and advanced therapies.
So the real story is not only where Parkinson’s is more common. It is where Parkinson’s is better organized. And across Europe, that answer is still uneven.
❓ FAQs
1. Is Parkinson’s more common in Western Europe than in Eastern Europe?
Broadly yes in terms of diagnosed burden and future growth, but the gap is more of a gradient than a dramatic divide. Western Europe is projected to grow by about 50% in case numbers by 2050, versus about 28% in Central and Eastern Europe.
2. What percentage of adults in Europe are affected?
A practical summary is roughly 0.2% to 0.4% of adults, based on representative European population studies, though it rises much higher in older age groups.
3. What are some example country figures?
Germany reported 0.35% of the population in 2022, Norway about 0.20% to 0.23%, Italy about 0.19%, and Poland about 0.27%.
4. Does Parkinson’s mainly affect older adults?
Yes. In Germany, prevalence was reported at 0.61% from age 40 and 1.42% from age 65, showing how sharply risk rises with age.
5. How many people in Europe are living with Parkinson’s now?
Parkinson’s Europe says about 1.2 million people in Europe are living with the condition.
6. Is there one unified European Parkinson’s care system?
No. European policy reports describe major differences between and within countries, including a postcode lottery in access to specialist support and advanced therapies.
7. Which European country is often cited as a model for network care?
The Netherlands is frequently highlighted because of ParkinsonNet, an integrated, person-centered care model.
8. What makes Germany different?
Germany has a formal reimbursed inpatient multidisciplinary program called PD-MCT, used in more than 200 hospitals.
9. Are Central and Eastern Europe mainly struggling with access?
In many places, yes. European reports and a recent Latvia pilot point to unequal specialist access, travel burden, and fragmented care pathways.
10. What is the simplest practical takeaway?
Prevalence differences across Europe are real but moderate. Care-system differences are often bigger. Where a person lives can strongly influence how quickly Parkinson’s is diagnosed, reviewed, and treated.
I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. Learn more |